Literature DB >> 11742478

The prevalence of avascular necrosis in patients treated with chemotherapy for testicular tumours.

A M Cook1, A S Dzik-Jurasz, A R Padhani, A Norman, R A Huddart.   

Abstract

To study the prevalence of avascular necrosis in patients receiving chemotherapy for testicular cancer we invited 103 consecutive patients treated by chemotherapy to attend for MRI scan of the hips. Four of 47 (9% (CI 2-20%)) patients scanned and 4/103 (3.8% (CI 1-10%)) of patients invited to participate in the study had evidence of avascular necrosis. As not all patients in the study had completed the at risk period this equates to a 3-year actuarial risk of 6.3% (95% confidence limits (CI) 2.4-16.1). These data suggest that avascular necrosis is an uncommon but significant complication of chemotherapy including steroids as anti-emetics. (c) 2001 Cancer Research Campaign

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11742478      PMCID: PMC2363966          DOI: 10.1054/bjoc.2001.2155

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  10 in total

1.  Avascular necrosis of the femoral head after treatment of Hodgkin's disease.

Authors:  V Tombolini; A Capua; E Pompili
Journal:  Acta Oncol       Date:  1992       Impact factor: 4.089

2.  Avascular necrosis of bone after adult acute lymphocytic leukemia treatment with methotrexate, vincristine, L-asparaginase, and dexamethasone (MOAD).

Authors:  L Hui; P H Wiernik
Journal:  Am J Hematol       Date:  1996-07       Impact factor: 10.047

3.  Avascular necrosis of the femoral head: association with adjuvant chemotherapy for breast carcinoma.

Authors:  M Perloff; G J Lesnick
Journal:  Cancer Treat Rep       Date:  1980 Feb-Mar

4.  Avascular necrosis in patients treated with BEP chemotherapy for testicular tumours.

Authors:  A M Cook; H Patterson; J Nicholls; R A Huddart
Journal:  Clin Oncol (R Coll Radiol)       Date:  1999       Impact factor: 4.126

Review 5.  Avascular necrosis following extensive chemotherapy and dexamethasone treatment in a patient with advanced ovarian cancer: case report and review of the literature.

Authors:  H Gogas; D Fennelly
Journal:  Gynecol Oncol       Date:  1996-12       Impact factor: 5.482

Review 6.  Avascular necrosis.

Authors:  R Mirzai; C Chang; A Greenspan; M E Gershwin
Journal:  Compr Ther       Date:  1998-05

7.  The problem of avascular necrosis of bone in patients treated for Hodgkin's disease.

Authors:  J J Mould; N M Adam
Journal:  Clin Radiol       Date:  1983-03       Impact factor: 2.350

8.  Avascular necrosis of bone after allogeneic bone marrow transplantation: clinical findings, incidence and risk factors.

Authors:  G Socié; F Sélimi; L Sedel; J Frija; A Devergie; H Esperou Bourdeau; P Ribaud; E Gluckman
Journal:  Br J Haematol       Date:  1994-03       Impact factor: 6.998

9.  Avascular necrosis of bone caused by combination chemotherapy without corticosteroids.

Authors:  P G Harper; C Trask; R L Souhami
Journal:  Br Med J (Clin Res Ed)       Date:  1984-01-28

10.  Avascular necrosis of bone complicating treatment of malignant lymphoma.

Authors:  J C Thorne; W K Evans; R E Alison; V Fournasier
Journal:  Am J Med       Date:  1981-11       Impact factor: 4.965

  10 in total
  8 in total

Review 1.  Musculoskeletal pain associated with corticosteroid therapy in cancer.

Authors:  Deborah A Frieze
Journal:  Curr Pain Headache Rep       Date:  2010-08

2.  Antiemetic efficacy and safety of a combination of palonosetron, aprepitant, and dexamethasone in patients with testicular germ cell tumor receiving 5-day cisplatin-based combination chemotherapy.

Authors:  Shota Hamada; Shiro Hinotsu; Koji Kawai; Shigeyuki Yamada; Shintaro Narita; Tomomi Kamba; Hiroyuki Nishiyama; Yoichi Arai; Tomonori Habuchi; Osamu Ogawa; Koji Kawakami
Journal:  Support Care Cancer       Date:  2014-03-21       Impact factor: 3.603

3.  2016 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting.

Authors:  Lawrence H Einhorn; Bernardo Rapoport; Rudolph M Navari; Jørn Herrstedt; Mary J Brames
Journal:  Support Care Cancer       Date:  2016-11-04       Impact factor: 3.603

Review 4.  Complications associated with chemotherapy in testicular cancer management.

Authors:  Chunkit Fung; David J Vaughn
Journal:  Nat Rev Urol       Date:  2011-03-15       Impact factor: 14.432

Review 5.  Chemotherapy-associated osteonecrosis in cancer patients with solid tumours: a systematic review.

Authors:  Katharine Shim; Mary J MacKenzie; Eric Winquist
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

6.  Phase II study of fosaprepitant + 5HT3 receptor antagonist + dexamethasone in patients with germ cell tumors undergoing 5-day cisplatin-based chemotherapy: a Hoosier Cancer Research Network study.

Authors:  Nabil Adra; Costantine Albany; Mary J Brames; Somer Case-Eads; Cynthia S Johnson; Ziyue Liu; Christopher A Fausel; Timothy Breen; Nasser H Hanna; Ralph J Hauke; Joel Picus; Lawrence H Einhorn
Journal:  Support Care Cancer       Date:  2016-02-02       Impact factor: 3.603

Review 7.  Management of Chemotherapy Induced Nausea and Vomiting in Patients on Multiday Cisplatin Based Combination Chemotherapy.

Authors:  Praveen Ranganath; Lawrence Einhorn; Costantine Albany
Journal:  Biomed Res Int       Date:  2015-09-03       Impact factor: 3.411

Review 8.  Toxicities Associated with Cisplatin-Based Chemotherapy and Radiotherapy in Long-Term Testicular Cancer Survivors.

Authors:  Chunkit Fung; Paul Dinh; Shirin Ardeshir-Rouhani-Fard; Kerry Schaffer; Sophie D Fossa; Lois B Travis
Journal:  Adv Urol       Date:  2018-02-18
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.